Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Perfect NEWS !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1191)
•••
Comment by Moemoney42on Jul 27, 2021 8:19pm
97 Views
Post# 33614633

RE:RE:RE:RE:Perfect NEWS !

RE:RE:RE:RE:Perfect NEWS ! Yes Whisky11.. you pretty much have him pegged.. he only cares about hoping someone might loose money on an investment in a short few days span, and doesn't have the foresight to think that Claritas may have a good treatment for any respiratory virus and save lives.. pretty much a BB troll that follows me around beaking off.. not happy with his investment, so to make himself feel worthy, he trash talks anything he's not invested in.. sad existance actually.. 
whisky11 wrote: Kaiser]

LOL! Moe pumping this dumpster fire?! Bahahhahha This guys track record is laughable at best.  This is the same clown who pumped Sona and you know where that is.

Like I said this was a gift to shorts post rs!
Back down to reality.  Poor no more money moe.

whisky11: so what's wrong with R-107
No information? Do you  see short activity today or yesterday? You sound like idiot



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities